Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial

Reuters2026/07/22 11:00

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Radiopharm Theranostics partnered with Siemens Healthineers to manufacture and distribute 18F-labeled RAD101 doses for a planned U.S. Phase 3 pivotal trial.
Collaboration follows Phase 2b results showing 93% concordance between RAD101 PET and MRI across evaluable lesions.
Radiopharm targets Phase 3 initiation in Q4 2026; RAD101 holds FDA Fast Track designation for recurrent brain metastases imaging.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220700PRIMZONEFULLFEED1001213823) on July 22, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial

You may also like

Crypto prices